Stephanie Davis
Stock Analyst at Barclays
(0.58)
# 4,159
Out of 5,115 analysts
94
Total ratings
31.82%
Success rate
-110.09%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $190 → $195 | $187.03 | +4.26% | 7 | Oct 22, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $26.56 | +69.43% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $10.76 | -53.53% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $37.47 | +100.16% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.07 | -0.99% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.27 | +164.32% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $3.21 | +491.90% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $359.22 | -19.27% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $214.88 | -38.10% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $48.49 | +19.61% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $4.04 | -25.74% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $271.52 | -8.29% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $13.43 | +115.93% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $5.45 | +523.85% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $23.87 | +42.44% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $203.92 | +14.26% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $2.15 | +690.70% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $85.59 | -11.20% | 5 | Jun 7, 2022 |
Quest Diagnostics
Oct 22, 2025
Maintains: Equal-Weight
Price Target: $190 → $195
Current: $187.03
Upside: +4.26%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $26.56
Upside: +69.43%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $10.76
Upside: -53.53%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $37.47
Upside: +100.16%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.07
Upside: -0.99%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.27
Upside: +164.32%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $3.21
Upside: +491.90%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $359.22
Upside: -19.27%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $214.88
Upside: -38.10%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $48.49
Upside: +19.61%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $4.04
Upside: -25.74%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $271.52
Upside: -8.29%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $13.43
Upside: +115.93%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $5.45
Upside: +523.85%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $23.87
Upside: +42.44%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $203.92
Upside: +14.26%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $2.15
Upside: +690.70%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $85.59
Upside: -11.20%